Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT03661866
Active, not recruiting Observational

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

NCT03661866 · tracked via the Priya Life Science USA tracker
Sponsor
Target PharmaSolutions, Inc
Phase
Observational
Started
2018-12-21
Last updated
2026-03-20

Condition(s) studied

Atopic DermatitisAlopecia AreataHidradenitis SuppurativaVitiligoPsoriasisChronic Spontaneous Urticaria

Study summary

TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * 1\. Adults and children (all ages) with Atopic Dermatitis or other Immune-mediated Inflammatory Skin Conditions been prescribed any dermatologic treatment. * 2\. Participant has plans for future visits at the site for continued management of IMISC. Exclusion Criteria: * 1\. Inability to provide written informed consent/assent. * 2\. Subjects participating in any interventional study or trial for IMISC treatment trial at the time of enrollment. Patients may be enrolled in TARGET-DERM once participation in the trial is complete. Note: Participants may be enrolled in other registries or studies where IMISC treatment outcomes are observed and/or reported (such as center-based registries).

Primary outcome measure(s)

  • Characterize IMISC Treatment Regimens in Clinical Practice — 25 Years
    Enable characterization of IMISC disease activity and comorbid medical conditions over time.
  • Evaluate Patient Outcomes in Clinical Practice — 25 Years
    Enable characterization of IMISC disease activity and comorbid medical conditions over time.
  • Evaluate Adverse Events of IMISC and treatment in Clinical Practice — 25 Years
    Enable characterization of IMISC disease activity and comorbid medical conditions over time.

Trial sites (62)

FacilityCityRegionStatus
Clear Dermatology & Aesthetics Center/Investigative MD Scottsdale Arizona
Johnson Dermatology Fort Smith Arkansas
University of Arkansas for Medical Sciences Little Rock Arkansas
Arkansas Dermatology Little Rock Arkansas
First OC Dermatology Fountain Valley California
Center for Dermatology Cosmetic and Laser Surgery Fremont California
University of California Irvine California
University of California - San Diego/Rady Children's Hospital San Diego California
George Washington University Washington D.C. District of Columbia
Feinstein Dermatology and Cosmetic Surgery Hollywood Florida
Academic Alliance in Dermatology Tampa Florida
Integrated Dermatology of West Palm Beach West Palm Beach Florida
Lurie Children's Hospital/Northwestern University Chicago Illinois
Dawes Fretzin Dermatology/ Dawes Fretzin Clinical Research Group Indianapolis Indiana
The University of Kansas Medical Center Kansas City Kansas
Family Allergy and Asthma Research Institute Louisville Kentucky
DermAssociates, LCC Rockville Maryland
Integrated Dermatology of Massachusetts Quincy Massachusetts
University of Massachusetts Medical School Worcester Massachusetts
University of Minnesota Minneapolis Minnesota
Mayo Clinic Rochester Minnesota
Carl Thornblade, MD, PLLC Missoula Montana
South Lincoln Dermatology Clinic Lincoln Nebraska
Advanced Dermatology of the Midlands Omaha Nebraska
Dartmouth-Hitchcock Medical Center Lebanon New Hampshire
Windsor Dermatology East Windsor New Jersey
Linda Susan Marcus Wyckoff New Jersey
Centurion Dermatology Brooklyn New York
The University of Buffalo Buffalo New York
Empire Dermatology East Syracuse New York
Forest Hills Dermatology Group Forest Hills New York
Greenwich Village Dermatology New York New York
Ichan School of Medicine New York New York
Advanced Allergy & Asthma, PLLC Rockville Centre New York
Montefiore Medical Center The Bronx New York
Allergy Partners of Western North Carolina Asheville North Carolina
UNC Dermatology Chapel Hill North Carolina
Wake Forest University Health Sciences Winston-Salem North Carolina
Ohio State University Columbus Ohio
Allergy, Asthma & Clinical Research Center Oklahoma City Oklahoma

+ 22 more sites — see the full list on the official registry below.

More Target PharmaSolutions, Inc. trials in the USA

An Observational Study of Patients With Chronic Gastrointestinal Disease Active, not recruiting
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC Active, not recruiting
An Observational Study of Patients With Dermatologic Disease Starting soon
An Observational Study of Patients With Chronic Liver Disease Enrolling by invitation
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease Active, not recruiting

Other trials for the same condition

A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis Recruiting
Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data Active, not recruiting
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting
A Journey Into Participation Patterns Among Patients With Hidradenitis Suppurativa Starting soon
A Study of LAD603 in Adults With Alopecia Areata Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03661866 on ClinicalTrials.gov ↗ ← All trials in the USA